Applied Integrin Sciences, Inc. discovers, develops and commercializes protein drug therapies for cancer treatments that reduce solid tumor growth and progression and improve patient survival and quality of life.
The Company's Founder-Scientists discovered a proprietary drug discovery platform for producing novel, first-in-class protein therapeutics modulating specific integrin receptors known to be involved in cancer growth, progression, and metastasis. These recombinant proteins affect primary tumors, tumor vasculature, and metastatic foci involved in cancer, as in the metastatic breast cancer cell shown in the image above.
The novel mechanism of action of Vicrostatin, the company's first candidate, and ADM01, one of twenty-three proprietary ADAM-Derived Disintegrin drug candidates, produces equally substantial reduced tumor progression in six aggressive metastatic tumors in vivo: triple negative breast cancer, primary prostate cancer, prostate cancer bone metastasis, ovarian cancer, melanoma, and glioblastoma.
Development on the recombinant drug candidates has been funded by the California Breast Cancer Research Program, Susan G. Komen for the Cure, National Institutes of Health, National Cancer Institute, and the Department of Defense. The NIH recently awarded the company a grant for ovarian cancer.